[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

New Dry Macular Degeneration Pipeline Review for H1 2012 Provided by Global Markets Direct

04 Sep 2012 • by Natalie Aster

In dry macular degeneration, waste products from the photo receptors accumulate underneath the retinal pigment epithelium (RPE), according to the report “Dry (Atrophic) Macular Degeneration – Pipeline Review, H1 2012” by Global Markets Direct. The wastes appear as yellowish spots called drusen. When drusen are present for a long time, the macula may thin and stop working. This is referred to as atrophy or atrophic macular degeneration and it often causes a slow and progressive loss of vision. Signs and symptoms are vision blurriness.

Global Markets Direct’s, Dry (Atrophic) Macular Degeneration – Pipeline Review, H2 2012, provides an overview into the pipeline. This report provides information on the current developmental pipeline, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews the key players and their products under development for Dry (Atrophic) Macular Degeneration. It is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Report Details:

Dry (Atrophic) Macular Degeneration – Pipeline Review, H1 2012
Published: June, 2012
Price: US$ 500,00


  • A snapshot of the global therapeutic scenario for Dry (Atrophic) Macular Degeneration. 
  • A review of the Dry (Atrophic) Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages. 
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics. 
  • Coverage of the Dry (Atrophic) Macular Degeneration pipeline on the basis of route of administration and molecule type. 
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. 
  • Key discontinued pipeline projects. 
  • Latest news and deals relating to the products.

More information can be found in the report “Dry (Atrophic) Macular Degeneration – Pipeline Review, H1 2012” by Global Markets Direct.

To order the report or ask for sample pages contact [email protected]


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]

Analytics & News

Weekly Digest